Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress

Vascul Pharmacol. 2007 Jun;46(6):427-38. doi: 10.1016/j.vph.2007.01.001. Epub 2007 Jan 23.

Abstract

Aim: We have previously proved that oxidized low-density lipoprotein (oxLDL), a proatherogenic lipoprotein, plays a pivotal role in the development of atherosclerotic calcification (AC). The present study was performed to investigate whether tanshinone II A (TS II A), an anti-oxidant which has been shown to inhibit in vitro oxidation of LDL, has the effects to inhibit AC in rat model and by which, if any, mechanisms.

Methods: Rat AC model was induced by excessive vitamin D(2) (VD) and high cholesterol diet (HCD), which was proven to be successful histopathologically and biochemically.

Results: Administration of AC rats with TS II A (35, 70 mg/kg) dose-dependently attenuated the AC pathological changes, meanwhile reduced the vessel contents of lipid and calcium. However, TS II A had no effects on serum levels of lipids, calcium and 25-OH VD. Further studies revealed that TS II A decreased serum concentration of oxLDL, reduced the superoxide anion production and malondialdehyde (MDA) in vessel. In addition, TS II A increased vessel Cu/Zn SOD activity, upregulated vessel mRNA and protein expression of Cu/Zn SOD.

Conclusion: The results suggested that TS II A significantly attenuated the AC in rat model, which might be attributed to its inhibition of oxLDL production independent of the serum levels of lipids, calcium and 25-OH VD, and that increasing of Cu/Zn SOD activity as well as mRNA and protein expression by TS II A might protect LDL against oxidation induced by superoxide anion in vessel.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abietanes
  • Animals
  • Antioxidants / pharmacology*
  • Antioxidants / therapeutic use
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism
  • Aorta, Thoracic / pathology
  • Atherosclerosis / chemically induced
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Atherosclerosis / prevention & control*
  • Calcinosis / chemically induced
  • Calcinosis / metabolism
  • Calcinosis / pathology
  • Calcinosis / prevention & control*
  • Calcium / metabolism
  • Cholesterol / metabolism
  • Cholesterol, Dietary
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Enzyme Induction / drug effects
  • Ergocalciferols
  • Lipoproteins, LDL / blood
  • Male
  • Malondialdehyde / metabolism
  • Oxidative Stress / drug effects*
  • Phenanthrenes / pharmacology*
  • Phenanthrenes / therapeutic use
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Sprague-Dawley
  • Superoxide Dismutase / biosynthesis
  • Superoxide Dismutase / genetics
  • Superoxides / metabolism
  • Time Factors

Substances

  • Abietanes
  • Antioxidants
  • Cholesterol, Dietary
  • Ergocalciferols
  • Lipoproteins, LDL
  • Phenanthrenes
  • RNA, Messenger
  • oxidized low density lipoprotein
  • tanshinone
  • Superoxides
  • Malondialdehyde
  • Cholesterol
  • Superoxide Dismutase
  • Calcium